In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas

Clinical Endocrinology

Volumn 54, Issue 1, 2001, Pages 23-30

  Andersen, Marianne ^a   Bjerre, Per ^a   Schrøder, Henrik D ^a   Edal, Anette ^a   Høilund Carlsen, Poul F ^a   Pedersen, Per Hyltoft ^a   Hagen, Claus ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FOLLITROPIN; LUTEINIZING HORMONE; OCTREOTIDE; PROTIRELIN; SODIUM CHLORIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ALPHA CHAIN; ARTICLE; CLINICAL ARTICLE; FEMALE; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPOPHYSIS ADENOMA; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PERIMETRY; PRIORITY JOURNAL; PROTIRELIN TEST; TUMOR VOLUME; VISUAL FIELD;

ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROGNOSIS; THYROTROPIN;

EID: 0035135295     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01172.x     Document Type: Article

References (30)

1. Cabergoline in the treatment of acromegaly: A study in 64 patients
2. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membranebound dopamine receptors which bind bromocriptine
3. Dopamine agonists and pituitary tumor shrinkage
4. Hormone production in clinically nonfunctioning pituitary adenomas
5. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide
6. Free luteinizing-hormone beta-subunit in normal subjects and patients with pituitary adenomas
7. Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: Anterior pituitary function and the effect of thyrotrophin-releasing hormone
8. Recognition of gonadotroph adenomas in women
9. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone
10. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro
11. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand
12. Acute effects on visual function of a somatostatin analog (SMS 201-995) evaluated using a neurophysiological approach
13. Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours
14. The use of betasubunits of gonadotrophin hormones in the follow-up of clinically non-functioning pituitary tumours
15. Endocrine-inactive, FSH, LH and alpha-subunit adenomas: Clinical findings and endocrinology
16. Demonstration of specific dopamine receptors on human pituitary adenomas
17. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine
18. Imaging and medical management of clinically nonfunctioning pituitary tumors
19. Volume of pituitary macroadenomas: Assessment by MRI
20. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas
21. Preoperative octreotide treatment of growth hormonesecreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy
22. The effect of thyrotropinreleasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors
23. Pulsatile glycoprotein hormone secretion in glycoprotein-producing pituitary adenomas
24. Management of pituitary tumors
25. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas
26. Antiproliferative effect of the somatostatin analogue octreotide on growth hormoneproducing pituitary tumors: Results of a multicenter randomized trial
27. Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue
28. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas
29. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas
30. LH and FSH secretion and responses to GnRH and TRH in patients with clinically functionless pituitary adenomas